Muzaffar H. Qazilbash, MD
Muzaffar Qazilbash is a Professor of medicine and Director of myeloma transplantation and cellular therapy in the Department of Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center. He is a non resident scholar for biomedical research policy in the Center for Health and Biosciences.
Qazilbash obtained his medical degree from the University of Karachi, Pakistan. He was trained in internal medicine at the University of Connecticut and in hematology and oncology at the National Institute of Health in Bethesda, Maryland.
Qazilbash’s research focuses on the development of novel therapies for stem cell transplantation and immunotherapy for patients with multiple myeloma, a common blood cancer. He has successfully taken cancer vaccines from basic science laboratories to clinical trials for patients with blood cancers. His research also focuses on improving the safety and effectiveness of stem cell transplants for patients with blood cancers. Qazilbash has authored or co-authored more than 175 peer-reviewed articles in medical journals and is a member of several professional societies, and takes keen interest in health policy and its impact on biomedical research. He is also a practicing hematologist at the MD Anderson Cancer Center.
Representative Publications:
High-Dose Therapy and Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Disease: Outcome Based on a Prognostic Model
Utility of a Prognostic Scoring System for Allogeneic Stem Cell Transplantation in Patients With Chronic Myeloid Leukemia
Nonmyeloablative Stem Cell Transplantation for Chronic Myeloid Leukemia
Second Autologous or Allogeneic Transplantation After The Failure of First Autograft in Patients With Multiple Myeloma
